DAY ONE BIOPHARMACEUTICALS
LIVE

Serial Number

98975225

Owner

Day One Biopharmaceuticals, Inc.

Attorney

Maury M. Tepper, III

First Use Date

Apr 23, 2024

Filing Date

Sep 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DAY ONE BIOPHARMACEUTICALS Trademark

Serial Number: 98975225 • Registration: 8189842

DAY ONE BIOPHARMACEUTICALS is a trademark filed by Day One Biopharmaceuticals, Inc. on September 21, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Day One Biopharmaceuticals, Inc.

1800 Sierra Point Parkway, Suite 200
Brisbane, CA 94005

Entity Type: 03

Trademark Details

Filing Date

September 21, 2023

Registration Date

March 24, 2026

First Use Anywhere

April 23, 2024

First Use in Commerce

April 23, 2024

Published for Opposition

May 20, 2025

Goods & Services

Educational services, namely, providing online newsletters in the field of prescription drug information via emails, non-downloadable webinars, and online non-downloadable videos in the field of prescription drug information; educational services, namely, providing prescription drug dosage training; educational services, namely, providing online non-downloadable videos in the field of treatment and diagnosis of tumors and cancer; educational services, namely, providing online non-downloadable videos in the field of treatment and diagnosis of pediatric low-grade glioma; educational services, namely, providing online non-downloadable videos for healthcare service providers, caregivers, and patients in the field of tumors and cancer; educational services, namely, providing online non-downloadable videos for healthcare service providers, caregivers, and patients in the field of pediatric low-grade glioma; providing information regarding tumors and cancer, and pediatric low-grade glioma

Healthcare insurance administration services; healthcare insurance administration services, namely, providing benefit verification, authorization and re-authorization support, appeals support, and information regarding benefit updates; providing information about healthcare insurance plans; financial services, namely, assessing sources of and facilitating access by patients and their families to financial support from copay support, patient assistance programs (PAP), patient foundations and organizations; financial services, namely, administration of patient reimbursement programs

Pharmaceutical preparations for human use for treating cancer and oncological diseases; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of oncological, neurological, and immune system related diseases and disorders; medical preparations for the delivery of compounds to the body for the treatment and prevention of oncological, neurological, and immune system related diseases and disorders

Research, development, and product evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research laboratory analysis and research of drugs and pharmaceutical products; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of new products, namely, drugs and pharmaceuticals for the treatment and/or prevention of oncological, neurological, and immune system diseases and disorders; research, development, and medical evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; design, development, research, and testing of drugs and pharmaceuticals for the treatment and/or prevention of oncological, neurological, and immune system related diseases and disorders

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 16, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 16, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 16, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 16, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 16, 2026 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 24, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 24, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 4, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 4, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Feb 8, 2026 SUPC
USE AMENDMENT FILED
Jan 13, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 13, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 15, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 20, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 20, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 14, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 21, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 9, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 9, 2025 ERFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 10, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 10, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 10, 2025 COAR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 10, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 10, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 10, 2025 CNFR
DIVISIONAL PROCESSING COMPLETE
Oct 15, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 11, 2024 AITU
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2024 TEME
DIVISIONAL REQUEST RECEIVED
Sep 9, 2024 DRRR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 9, 2024 TROA
TEAS REQUEST TO DIVIDE RECEIVED
Sep 9, 2024 ERTD
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 6, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 6, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 27, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Oct 10, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 9, 2023 NWOS
NEW APPLICATION ENTERED
Sep 25, 2023 NWAP